1994
DOI: 10.1097/00007890-199410270-00008
|View full text |Cite
|
Sign up to set email alerts
|

ASSESSMENT OF SOLUBLE ADHESION MOLECULES (sICAM-1, sVCAM-1, sELAM-1) AND COMPLEMENT CLEAVAGE PRODUCTS (sC4d, sC5b-9) IN URINE

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

3
24
1
3

Year Published

1996
1996
2010
2010

Publication Types

Select...
8
2

Relationship

1
9

Authors

Journals

citations
Cited by 51 publications
(31 citation statements)
references
References 0 publications
3
24
1
3
Order By: Relevance
“…Soluble VCAM-1 in plasma is derived from shedding of endothelial cells and has also been related to endothelial dysfunction (26). In the absence of significant excretion of sVCAM-1 in the urine (27), plasma sVCAM-1 concentration can be regarded as a reflection of endothelial release. Finally, microalbuminuria is often regarded as a marker of generalized endothelial dysfunction and has been shown to be independently associated with impaired endothelium-dependent vasodilation (28).…”
Section: Discussionmentioning
confidence: 99%
“…Soluble VCAM-1 in plasma is derived from shedding of endothelial cells and has also been related to endothelial dysfunction (26). In the absence of significant excretion of sVCAM-1 in the urine (27), plasma sVCAM-1 concentration can be regarded as a reflection of endothelial release. Finally, microalbuminuria is often regarded as a marker of generalized endothelial dysfunction and has been shown to be independently associated with impaired endothelium-dependent vasodilation (28).…”
Section: Discussionmentioning
confidence: 99%
“…Among those are urinary IL-2, IL-8, and complement fragments such as soluble C4d (15)(16)(17). However, so far these predictors have not been introduced into clinical routine.…”
mentioning
confidence: 99%
“…An increasing number of clinical and experimental studies of renal and cardiac allografts have linked complement activation to alloantigen-independent and -dependent responses. Complement activation occurs during the perioperative period (1-4), acute rejection (5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17), and chronic graft dysfunction (18 -21). Split products of early complement components influence the localization, activation, and effector functions of platelets, granulocytes, monocytes, and lymphocytes, while membrane attack complex (MAC), 3 which is formed by the terminal components of complement (C5b-C9), can lead to rapid activation and destruction of target cells (1,4,22).…”
mentioning
confidence: 99%